SCHEMBL31443429

SCHEMBL31443429

COc1c(NS(=O)(=O)c2c(F)cccc2F)cccc1-c1nc(C(C)(C)C)sc1-c1ccnc(Cl)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 20/20 0.66
NR1I2 O75469 3/20 0.66
PLK4 O00444 1/20 0.66
EPHB6 O15197 1/20 0.66
RIPK2 O43353 1/20 0.66
JAK2 O60674 1/20 0.66
ULK1 O75385 1/20 0.66
ERN1 O75460 1/20 0.66
PRKD3 O94806 1/20 0.66
ABL1 P00519 1/20 0.66
KRAS P01116 1/20 0.66
RAF1 P04049 1/20 0.66
LCK P06239 1/20 0.66
FYN P06241 1/20 0.66
CDK1 P06493 1/20 0.66
YES1 P07947 1/20 0.66
LYN P07948 1/20 0.66
MET P08581 1/20 0.66
HCK P08631 1/20 0.66
FGR P09769 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127795 0.90 BRAF (0.70) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL1128208 0.90 BRAF (0.81) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2193316 0.87 BRAF (0.59) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL14733911 0.85 BRAF (0.73) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2194734 0.82 BRAF (0.60) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2191410 0.82 BRAF (0.69) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2194551 0.82 BRAF (0.72) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2193766 0.82 BRAF (0.64) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2193513 0.82 RIPK2 (0.52) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2194314 0.82 BRAF (0.84) BRAFNR1I2PLK4EPHB6RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072462-A1 SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed